8-K: U.S. Physical Therapy Q2 2025: Record Visits, Raised Guidance

U.S. Physical Therapy, Inc. reported record second-quarter 2025 visits and raised its full-year adjusted EBITDA guidance, driven by strong physical therapy and industrial injury prevention segment performance.

Summary

• A record second quarter for physical therapy volumes was achieved, with visits per clinic per day jumping to 32.7, up from 30.6 in Q2 2024.
• The company's Net Promoter Score (NPS) is 93.5, with 95% of patients being active promoters and only 1% detractors.
• Industrial Injury Prevention (IIP) revenues increased by 22.6% (18.4% organically), and gross profit rose by 25.8% (21.8% organically) compared to the prior year quarter.
• Physical Therapy (PT) revenues were strong, increasing by 17.3%, driven largely by acquisitions, including the Metro PT transaction which contributed $19.6 million.
• Over 50 net clinics were added compared to the prior year period, and total visits exceeded three million year-to-date for the first time.
• A slight increase in the net rate per patient visit to $105.33 was achieved despite Medicare headwinds and a negative policy change from a large payer in Michigan.
• Salaries and related costs per visit increased by a minimal 0.7%, while overall cost per visit decreased slightly.
• The PT gross profit margin improved to 21.1% for the quarter, up from 20.1% in Q2 2024.
• Adjusted EBITDA for Q2 2025 increased to $26.9 million, up $4.7 million from Q2 2024, with the adjusted EBITDA margin expanding to 17.5%.
• Full-year 2025 adjusted EBITDA guidance was raised to a range of $93.0 million to $97.0 million, up from the previous range of $88.0 million to $93.0 million.
• New cash-based programs generated approximately $900,000 in additional revenue.
• A share repurchase program for up to $25.0 million of shares was authorized by the board of directors through December 31, 2026.

Sentiment

Score: 8

Explanation: Strong operational and financial results were reported, including record volumes, improved margins, and raised guidance. Positive developments in the IIP segment and effective cost management are notable. While Medicare headwinds persist, the outlook for 2026 rates is positive. The share repurchase authorization signals management confidence. The only minor concerns are slight tapering in June volumes and specific regional payer issues, but overall sentiment is very positive.

Positives

• Record second quarter for physical therapy volumes (32.7 visits/clinic/day) was achieved, the highest in company history.
• An exceptional Net Promoter Score (NPS) of 93.5 was reported, significantly surpassing healthcare industry benchmarks.
• Strong growth in the Industrial Injury Prevention (IIP) segment was observed, with 22.6% revenue increase and 25.8% gross profit increase year-over-year.
• Significant increase in Physical Therapy (PT) revenues by 17.3% was driven by strategic acquisitions and organic growth.
• Effective cost management was demonstrated, with salaries and related costs per visit increasing only 0.7% and total operating costs per visit decreasing year-over-year.
• PT gross profit margin improved to 21.1%, the highest quarterly margin since Q2 2023.
• Full-year 2025 adjusted EBITDA guidance was raised to $93.0 $97.0 million, reflecting strong performance and confidence.
• Successful launch and ramp-up of cash-based programs generated $900,000 in additional revenue.
• Clinician turnover rates are at their lowest in seven years, attributed to investments in recruiting and retention.
• A positive outlook for 2026 Medicare rates is anticipated, with an estimated increase of 1% to 1.75%, translating to a $2-$3 million top-line benefit.
• A strong balance sheet was maintained, with $34.1 million in cash and a $175.0 million revolving credit facility.
• A share repurchase program was authorized, providing flexibility and demonstrating confidence in company valuation.

Negatives

• Medicare rate cuts continue to be a significant headwind, impacting profit by approximately $25 million this year and $5-$6 million compared to last year.
• A slight tapering of average visits per day in June (32.3) was consistent with historic summer patterns.
• Net rate per patient visit was slightly less than Q1 2025 ($105.33 vs. $105.66).
• A policy change by a large payer in Michigan negatively impacted the net rate in that state.
• Same-store visit growth for mature facilities was lighter than expected, though still over 1%.
• Staffing remains tight in a few markets, which may slightly dampen growth.
• Implementation costs for a new enterprise-wide financial and human resources system will continue through 2026.

Risks

• Continued Medicare rate reductions or unfavorable policy changes from government payers pose a risk.
• Challenges in staffing and retaining qualified clinicians, particularly in tight labor markets, could impact capacity and growth.
• Impact of policy changes from large commercial payers on net rates could affect profitability.
• Uncertainty regarding the final 2026 Medicare Physician Fee Schedule ruling remains until December.
• Competition in the physical therapy and industrial injury prevention markets could intensify.
• Ability to successfully integrate and realize synergies from future acquisitions is crucial for sustained growth.
• Economic downturns could impact patient volumes or payer reimbursement.

Future Outlook

Full-year 2025 adjusted EBITDA guidance was raised to a range of $93.0 million to $97.0 million, reflecting strong first-half performance and confidence in the second half. Management anticipates continued organic growth in the Industrial Injury Prevention business and ongoing physical therapy acquisitions. Preliminary estimates for 2026 Medicare rates suggest a positive increase of 1% to 1.75%, translating to a $2-$3 million top-line benefit and $1.5-$2.5 million EBITDA benefit. Plans include continued focus on rate-enhancing initiatives, including targeted contract negotiations and growing higher net rate workers' comp business. New initiatives to impact costs and drive volume are gaining traction, and the company expects to continue ramping up de novo clinic openings.

Management Comments

• Our industrial injury prevention partnerships are really firing on all cylinders at this point. We've added a number of very large opportunities, some of which haven't even started yet.
• Our net promoter score is 93.5. Just to give you some perspective, before this call, I googled, 'What's a good net promoter score for a healthcare company,' and I got two answers: good was 30 and excellent was 50.
• To grow over 20% with that kind of a headwind consistently, we're really happy right now about things that are coming together.
• We're feeling better about things right now than we have for some time.
• We still have plenty of things to work on, right, which to me, is also encouraging because we're not there yet. We have room for improvement.
• We feel like the stock's been undervalued for some time... So we wanted to be in a position to have flexibility at a certain level where we could go in and demonstrate our belief that we're going to continue to grow this company and do it well over time.
• Our first preference right now, frankly, is directed towards injury prevention where the embedded organic elements of that business are really, really strong.
• These are the lowest turnover rates we've seen for the six months this year, January through June. Lowest numbers we've seen in the last seven years.
• The irony is, unfortunately, if you get under the hood and see how the sausage is made, that the specialties that have the most extraordinary increases in the cost of equipment... physical therapy in general, doesn't have that problem.
• We need more than one year fix, for sure. And we have AMA and the Hospital Association and everybody else wants more than a year-to-year fix. It's unsustainable.

Industry Context

The physical therapy industry faces ongoing Medicare reimbursement headwinds, with the company absorbing a 2.9% rate reduction this year, impacting profits significantly. However, the preliminary 2026 Medicare Physician Fee Schedule proposes a positive rate increase, a welcome change after years of cuts, though the industry is advocating for a more stable multi-year solution. The company is leveraging technology like AI for clinical documentation and semi-virtualization for front desk operations, aligning with broader healthcare trends towards efficiency and digital integration. The Industrial Injury Prevention segment is benefiting from a potential push to onshore manufacturing in the U.S., creating large contract opportunities. The company's high Net Promoter Score (93.5) significantly surpasses industry averages (good at 30, excellent at 50 for healthcare), indicating strong patient satisfaction and a competitive advantage in patient referrals.

Comparison to Industry Standards

• A Net Promoter Score (NPS) of 93.5 is significantly higher than the industry benchmarks of 30 (good) and 50 (excellent) for healthcare companies.
• The ability to drive a slight increase in net rate despite Medicare headwinds (2.9% reduction) and specific payer policy changes (Michigan) demonstrates effective contract negotiation and strategic focus on higher-rate services like workers' compensation.
• The Metro PT acquisition's net rate increased from $101.00 to $107.50, showcasing successful integration and rate improvement strategies compared to typical acquisition performance.
• Clinician turnover rates are at their lowest in seven years, indicating superior retention strategies compared to a competitive labor market.
• Active involvement with APTQI (Alliance for Physical Therapy, Quality, and Innovation) to advocate for systemic changes in Medicare reimbursement, including leveraging results from the EQUIP study in Maryland where physical therapy acts as primary care for musculoskeletal cases, demonstrates a leadership position in industry advocacy for value-based care.

Stakeholder Impact

• Shareholders are positively impacted due to strong financial performance, raised guidance, share repurchase program, and potential for continued growth and profitability.
• Patients are highly impacted, indicated by a Net Promoter Score of 93.5, suggesting high satisfaction with care quality.
• Employees/Clinicians benefit from improved retention rates (lowest in seven years) due to investments in recruiting, retention, mentorship, and technology (AI for documentation), potentially leading to better work-life balance and job satisfaction.
• Customers (Industrial Injury Prevention) benefit from expanded service offerings and successful large contracts, indicating effective injury prevention and cost savings.
• Payers are engaged in ongoing contract negotiations and advocacy for Medicare reimbursement changes.

Next Steps

• Implementation of a new enterprise-wide financial and human resources system will continue through 2026.
• Implementation of the new system will start in the third quarter.
• Efforts to increase reimbursement rates through targeted contract negotiations will continue.
• Efforts to grow higher net rate workers' comp business will continue.
• Focus hard on injury prevention business development and capital deployment will continue.
• AI-backed technologies for clinical documentation will continue to be deployed.
• Semi-virtualization of the front desk will continue to be rolled out.
• Work with CMS and Congress to advocate for a multi-year fix for the Physician Fee Schedule will continue.
• The final 2026 Medicare ruling in December will be monitored.
• Cash-based programs will continue to ramp up.
• De novo clinics will continue to be opened.

Key Dates

Recommendation

The company delivered a very strong quarter with record volumes, significant revenue growth in both core segments, and improved profitability margins. The raised full-year EBITDA guidance signals robust confidence in continued performance. Strategic initiatives like the expansion of the high-margin Industrial Injury Prevention business, successful integration of acquisitions (Metro PT), and the introduction of cash-based programs are driving organic growth and diversification. Furthermore, effective cost management, particularly in labor, and the lowest clinician turnover in seven years, demonstrate operational excellence. The preliminary positive outlook for 2026 Medicare rates, after years of headwinds, removes a significant overhang. The authorized share repurchase program underscores management's belief in the stock's undervaluation. These factors collectively point to strong fundamentals, operational efficiency, and a positive future trajectory, making it a compelling investment.

Keywords

Physical Therapy, Industrial Injury Prevention, Healthcare Services, SEC Filing, Earnings Call, USPH, Clinic Operations, Patient Volume, Net Rate, EBITDA, Medicare, AI in Healthcare, Share Repurchase, Corporate Governance, Risk Management, Financial Reporting